Biocryst Pharmaceuticals Presents Results from Its BCX4208 Gout Program at the Annual European Congress of Rheumatology

Published: Jun 06, 2012

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that additional safety and efficacy results from its BCX4208 gout program will be presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in Berlin, Germany on June 7 & 8, 2012.

Back to news